Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
12.12.2022 - DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include: Two Additional Portfolio Programs (DARE-GML and ...
Source: wallstreet-online.de